Recent studies reveal glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer benefits in cardiovascular health, liver function, and quality of life for patients with obesity.
February, marked as American Heart Month, serves as a reminder of the importance of cardiovascular health, which remains the leading cause of death globally. In line with this focus, Endocrine News highlights recent research examining the effects of incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), on obesity and cardiovascular health. These studies delve into the impact of GLP-1RAs on various health metrics, including liver health, insulin sensitivity, and overall quality of life. Recent advancements in obesity treatment have demonstrated significant effectiveness in not only reducing weight but also improving cardiometabolic conditions.
GLP-1RAs have shown substantial promise for individuals suffering from obesity-related cardiovascular and metabolic issues, revealing synergistic benefits that extend beyond mere weight management. Despite these advancements, treatment discontinuation remains a challenge—many patients stop therapy within a year, often due to costs, accessibility issues, or side effects. However, there is increasing evidence that GLP-1RAs and their associated therapies could be crucial for high-risk groups that have previously been underrepresented in treatment approaches.
Key Findings:
The study titled “Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management,” published in Endocrinology, looks ahead at how these innovative agents may reshape treatment dynamics and reveal additional health benefits. Researchers, including Chao Zheng, PhD from The Second Affiliated Hospital at Zhejiang University in China, aim to broaden the potential demographic that could benefit from these therapies. They note that the effectiveness of GLP-1RAs is limited in a notable percentage of patients, prompting exploration into novel peptide-based therapies combining GLP-1RAs with other incretins such as GIP and glucagon.
The interaction between GIP and GLP-1 receptors may lead to enhanced metabolic control. For instance, tirzepatide, a co-agonist of GLP-1 and GIP, has demonstrated remarkable efficacy compared to single therapies. These new drugs target the multifaceted metabolic challenges posed by type 2 diabetes and obesity and their related complications, aiming to forge synergies that help regulate appetite, insulin secretion, liver metabolism, and energy expenditure.
For example, cotadutide, another recent agent, is a daily injectable that has shown improvements in liver metabolism and reduced levels of HbA1c, alongside protective effects on kidney functions. On the other hand, efinopegdutide has exhibited favorable weight loss results, although its safety profile shows variability compared to semaglutide.
Other promising dual agonists include survodutide, mazdutide, and pemvidutide, with observed benefits in weight management and cardiometabolic health. A GLP-1/GIP dual agonist like tirzepatide strengthens glycemic control by promoting insulin secretion while suppressing glucagon and delaying gastric emptying.
For comprehensive metabolic management, triple agonists such as retatrutide are under investigation, demonstrating significant reductions in HbA1c and body weight while showing promise in lowering liver fat and ameliorating metabolic dysfunction-related liver disease (MASLD).
As researchers continue to uncover the potential of these treatments, certain challenges remain. The authors emphasize the need for more clarity regarding the mechanisms of these innovative drugs, long-term safety profiles, and appropriate dosing strategies, alongside the development of personalized treatment approaches informed by individual biomarkers. The research team called for focused studies comparing different agents like tirzepatide and retatrutide, alongside validating biomarkers for guiding anti-inflammatory therapies.
In a separate study, titled “Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program,” Ambarish Pandey, MD, MSCS, along with colleagues from the University of Texas Southwestern Medical Center, presented compelling data on the effectiveness of semaglutide in patients with obesity-related HFpEF and frailty. Analyzing data from 1,145 participants, the team sought to understand a pressing concern: whether significant weight loss through medication could exacerbate frailty—particularly muscle loss—in already frail patients.
The findings confirmed that semaglutide yielded a notable average weight reduction of 8% to 9% from baseline compared to a placebo and, intriguingly, resulted in measurable improvements in frailty, especially among the most frail participants. “Improvements were significantly greater in frail patients, indicating the benefits extend beyond just weight loss,” stated Pandey.
He elaborated that the overlap of obesity, HFpEF, and frailty shares biological roots linked to chronic inflammation and metabolic inefficiencies. Remarkably, semaglutide appeared to address these interconnected pathways effectively, producing improvements even in patients with substantial initial dysfunction.
A year into treatment, semaglutide users reported an impressive 11-point enhancement on the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score, often transitioning to a less frail status. According to Pandey, this represents a transformative change that can considerably impact daily life beyond mere symptom management.
Semaglutide's multifaceted approach suggests it may not only relieve symptoms but also potentially alter the progression of obesity-related HFpEF conditions. The emerging data emphasizes the value of these therapies in not just treating additional obesity-related conditions but also in addressing frailty—a dual pressing concern in today's population.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.